Inanunsyo ng Department of Science and Technology (DOST) na ang clinical trial ng convalescent plasma transfusion bilang adjunctive therapy para mapigilan ang paglala ng COVID-19 sa mga pasyenteng na-ospital ay natapos na.
Ayon kay DOST Secretary Fortunato Dela Peña, natapos na ang pag-aaral noong June 30.
Ang pag-aaral ay pinondohan ng DOST-Philippine Council for Health Research and Development (PCHRD), at pinangunahan ito ni Dr. Deonne Thaddeus Gauiran ng University of the Philippines – Philippine General Hospital (UP-PGH).
Layunin ng pag-aaral na ma-evaluate ang efficacy at safety ng convalescent plasma para sa hospitalized COVID-19 patients.
“The proponent concluded that among hospitalized COVID-19 patients, no significant differences were observed in the need for ICU admission between patients given convalescent plasma therapy as adjunct to standard of care and those who received standard of care alone,” sabi ni Dela Peña.
Ang pag-aaral ay randomized, non-placebo controlled, open-label, single-centre clinical trial.
Ang convalescent plasma ay kinukuha mula sa dugo ng mga pasyenteng gumaling sa COVID-19 at naglalaman ng neutralizing antibodies laban sa virus.
